- Home
- IBCP vs MGTX Comparison
IBCP vs MGTX Comparison
Compare IBCP & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- MGTX
- Stock Information
- Founded
- IBCP 1864
- MGTX 2015
- Country
- IBCP United States
- MGTX United States
- Employees
- IBCP N/A
- MGTX N/A
- Industry
- IBCP Major Banks
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBCP Finance
- MGTX Health Care
- Exchange
- IBCP Nasdaq
- MGTX Nasdaq
- Market Cap
- IBCP 682.2M
- MGTX 701.5M
- IPO Year
- IBCP N/A
- MGTX N/A
- Fundamental
- Price
- IBCP $32.29
- MGTX $8.85
- Analyst Decision
- IBCP Hold
- MGTX Strong Buy
- Analyst Count
- IBCP 3
- MGTX 3
- Target Price
- IBCP $36.00
- MGTX $25.67
- AVG Volume (30 Days)
- IBCP 122.0K
- MGTX 441.5K
- Earning Date
- IBCP 10-28-2025
- MGTX 11-12-2025
- Dividend Yield
- IBCP 3.22%
- MGTX N/A
- EPS Growth
- IBCP N/A
- MGTX N/A
- EPS
- IBCP 3.06
- MGTX N/A
- Revenue
- IBCP $217,457,000.00
- MGTX $37,917,000.00
- Revenue This Year
- IBCP N/A
- MGTX $144.79
- Revenue Next Year
- IBCP $5.56
- MGTX $168.58
- P/E Ratio
- IBCP $10.54
- MGTX N/A
- Revenue Growth
- IBCP 2.56
- MGTX 366.84
- 52 Week Low
- IBCP $26.75
- MGTX $4.55
- 52 Week High
- IBCP $40.32
- MGTX $9.44
- Technical
- Relative Strength Index (RSI)
- IBCP 56.74
- MGTX 58.83
- Support Level
- IBCP $31.24
- MGTX $8.42
- Resistance Level
- IBCP $32.38
- MGTX $9.17
- Average True Range (ATR)
- IBCP 0.69
- MGTX 0.62
- MACD
- IBCP 0.15
- MGTX 0.06
- Stochastic Oscillator
- IBCP 89.59
- MGTX 70.28
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.